Amylyx Pharmaceuticals, Inc. - 8-K Filing
Amylyx Pharmaceuticals held its Annual Meeting of Stockholders on June 4, 2026, where stockholders voted to elect George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors; ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026; and approved on a non-binding advisory basis the compensation of named executive officers. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $AMLX